14M135: State-of-the-Art: The Jury on JAKs: JAK Inhibitors’ Future in Rheumatic Diseases

Monday, November 14, 2022

12:00 PM – 1:00 PM Eastern Time

Location: Terrace Ballroom II&III

CE: 1

All of the relevant financial relationships listed for faculty have been mitigated.

Moderator(s)

Christie M. Bartels, MD, MS

Rheumatologist
University of Wisconsin School of Medicine and Public Health
Madison, WI, United States

Disclosure(s): Independent Grants for Learning & Change (Pfizer): Grant/Research Support (Ongoing)
NS

Namrata Singh, MD, MSc

University of Washington
Bellevue, WA, United States

Disclosure(s): No financial relationships with ineligible companies to disclose

Despite FDA approval for tofacitinib and other JAK inhibitors for use in RA, PsA, AS, JIA and UC (following prior and new black box warnings), many rheumatologists are left wondering about their role in treatment. This session will examine data from the 2022 NEJM published study that led to new black box warnings, and will address remaining questions regarding class effects and optimal use.

Learning Objectives:

Review current JAK inhibitor mechanisms, applications, and black box warnings
Critically appraise the data behind the new black box warnings
Examine special population characteristics to guide risk stratification and targeted use

Presentations:

12:00 PM – 12:45 PM Eastern Time

The Jury on JAKs: JAK Inhibitors' Future in Rheumatic Diseases
Speaker: Jon T. Giles, MD, MPH – Columbia University
12:45 PM – 1:00 PM Eastern Time

Q&A